Literature DB >> 22521058

Insulin degludec: a new ultra-longacting insulin.

Abd A Tahrani1, Clifford J Bailey, Anthony H Barnett.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521058     DOI: 10.1016/S0140-6736(12)60527-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.

Authors:  Gerald H Tomkin
Journal:  World J Diabetes       Date:  2014-10-15

Review 2.  Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 3.  Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons.

Authors:  Naeema Hanif; Hezhou Wu; Peizhou Xu; Yun Li; Amir Bibi; Asma Zulfiqar; Muhammad Zafar Iqbal; Muhammad Tahir; Xiangyang Zhang; Asif Ali
Journal:  Curr Issues Mol Biol       Date:  2022-02-11       Impact factor: 2.976

4.  Clinical utility of insulin and insulin analogs.

Authors:  Ahter D Sanlioglu; Hasan Ali Altunbas; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Islets       Date:  2013-03-01       Impact factor: 2.694

5.  Insulin therapies: Current and future trends at dawn.

Authors:  Subhashini Yaturu
Journal:  World J Diabetes       Date:  2013-02-15

6.  Persistent Hypoglycemia Induced by Long-acting Insulin Degludec.

Authors:  Yukino Katakura; Fuminori Tatsumi; Takashi Kusano; Masashi Shimoda; Kenji Kohara; Tomohiko Kimura; Atsushi Obata; Shuhei Nakanishi; Tomoatsu Mune; Kohei Kaku; Hideaki Kaneto
Journal:  Intern Med       Date:  2021-09-04       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.